Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

NCT01188564 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema

Interventions

DRUG: rhC1INH
DRUG: Placebo (Saline)

Sponsor

Pharming Technologies B.V.